<DOC>
	<DOCNO>NCT00401206</DOCNO>
	<brief_summary>To determine safety effectiveness dexmedetomidine administer conscious sedation flexible bronchoscopy ( FB ) patient Chronic Obstructive pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Use Dexmedetomidine Sedation During Flexible Bronchoscopy Patients With COPD : A Descriptive Study</brief_title>
	<detailed_description>This pilot study design provide preliminary data use dexmedetomidine outpatient FB procedures require sedation . Clinical parameter vital sign , level sedation , dose supplemental sedation , measure comfort evaluate population patient know Chronic Obstructive Lung Disease undergo elective FB . Patients COPD schedule outpatient FB provide intravenous infusion dexmedetomidine ( 1 mcg/kg/hr ) ( Precedex® : Hospira , Inc , Lake Forest , IL ) 15-30 min period procedure continue throughout procedure . No load dose use prior start infusion . The FB procedure conduct accord standard practice use routine monitoring technique . This dose regimen 1.0 mcg/kg/hr choose load dose omit since previous review document lack adverse event maintenance dose exceed 1 mcg/kg/hr . Drug infusion discontinue follow adverse event observe : recurrent apnea ( Respiratory Rate &lt; 7 ) last 30 second 5 min observation period , sustain episode ( 30 second ) hemoglobin oxygen saturation lower 90 % 5 min observation period , decrease heart rate 50 beats/min , mean arterial pressure 70 % initial value . If need , additional sedation provide alternate dos midazolam 1 mg , Fentanyl 25 mcg pain , agitation interfere completion procedure , persistent cough non-responsive local lidocaine instillation . The amount Fentanyl verse use adjunct conscious sedation also record part study . The quality sedation assess use Richmond Agitation Sedation Scale . The quality analgesia assess use 11-point ( 0-10 ) Numerical Pain Rating scale ( NRS ) . The level recovery anesthesia return psychomotor fitness assess use Modified Post anesthesia Discharge Scoring System ( MPADSS ) . The duration FB time end procedure patient reach score 9 10 MPADSS ( readiness discharge ) also measure . Except measurement describe ( NRS ) , additional procedure perform purpose study .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Subject COPD Subject ≥ 18 year age If female , subject nonlactating either able become pregnant proven pregnant actively practice birth control Subject subject 's legally authorize representative voluntarily sign date informed consent explain any/all question answer Subject α2 agonist contraindicate Subject opiate , benzodiazepine , dexmedetomidine contraindicate know suspected serious allergy drug might administer course study Subject meet follow cardiovascular criterion : ( A routine EKG perform potential subject prior enrollment order screen unrecognized conduction abnormality . ) Acute unstable angina ( define current hospital stay ) Myocardial infarction within 6 week bronchoscopy Suspicion acute myocardial infarction Known severe leave ventricular failure Heart rate &lt; 50 bpm prior infusion start Systolic blood pressure le 90 mmHg prior infusion start Conduction abnormalities except 1st degree AV block ratecontrolled atrial fibrillation ; subject functional pacemaker capacity enrol Known severe liver disease Subject require dialysis ( e.g. , hemodialysis , peritoneal dialysis , CVVHD ) Subject know , uncontrolled seizure disorder Subject αagonists blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>sedation</keyword>
	<keyword>bronchoscopy</keyword>
	<keyword>COPD</keyword>
</DOC>